Stoke's Faster Timeline Cuts the Wait to 2027 Data-But $411M Only Buys So Much Time

Faster enrollment gives Stoke a more active catalyst path

Stoke Therapeutics is moving from a passive waiting game toward a more near-term catalyst story.

The direction of the change matters. Earlier this year, management said the program was on pace for a Phase 3 data readout in mid-2027, with completion of enrollment of 150 patients in Q2 2026. In the latest update, the company said enrollment of 162 patients is complete and still pointed to data readout anticipated in Q3 2027. That is not a move to 2026 data, but it does mean the timeline has shifted from a generic mid-2027 expectation to a more specific Q3 2027 target.

For investors, that keeps the setup centered on one major near-term event: the EMPEROR study readout. Faster enrollment improves the odds that timelines stay intact, but it does not remove the stock's dependence on that dataset.

The main near-term job is to confirm that the faster pace is still holding rather than slipping again.

• January - J.P. Morgan Healthcare Conference: See whether management still describes accelerated timelines as intact.
• June - Jefferies and Goldman Sachs conferences: See whether the company's broader investor activity, including June 2026 conference participation, aligns with progress toward a 2027 data window and eventual regulatory filing.

If those checkpoints hold, Stoke remains a pre-data story with improving timing. If they do not, the stock is still likely to trade mainly around the single future readout rather than around current earnings or commercial revenue.